Home/Pipeline/FG-3246

FG-3246

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Phase 2Active

Key Facts

Indication

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Phase

Phase 2

Status

Active

Company

Kyntra Bio

About Kyntra Bio

Kyntra Bio is a private, pre-revenue biotech founded in 2021 and headquartered in Cambridge, Massachusetts. The company is developing a focused pipeline of innovative therapies, with its lead programs being roxadustat (Phase 3-ready for LR-MDS anemia) and FG-3246 (Phase 2 for mCRPC). Under CEO Thane Wettig, Kyntra leverages in-licensed assets and a platform-agnostic approach to target key biological pathways in cancer and anemia, with initial clinical data for its ADC expected in 2026.

View full company profile

Therapeutic Areas

Oncology Hematology

Other Metastatic Castration-Resistant Prostate Cancer (mCRPC) Drugs

Drug	Company	Phase	Status
Tomivosertib	eFFECTOR Therapeutics	Phase 2	Terminated
Gedatolisib + Darolutamide	Celcuity	Phase 1b/3	Active
SNP-101 (estimated)	SmartNuclide Biopharma	Phase 1	Active
AB001 (²¹²Pb-NG001)	ARTBIO	Phase 1/2	Active - First patient dosed in ARTISAN trial (Jan 2026)
AB-3028	Arsenal Biosciences	IND-Enabling	Active
PRO CAR-201A	PromiCell	Phase 1	Active
PRO CAR-202	PromiCell	Preclinical	Active
PROVENGE (sipuleucel-T)	Dendreon	Approved	Active
RP12146	Rhizen Pharmaceuticals	Phase 1b	Active
Monoclonal Antibody (undisclosed)	MetaCurUm Biotech	Preclinical	Active
ModraDoc006/r	Modra Pharmaceuticals	Phase 2b	Active
SYNC-T	Syncromune	Phase 2	Active